drugset / Trial / NCT04976153
Skeletal Muscle-derived Cell Implantation for Treatment of Fecal Incontinence
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this study is the final assessment of clinical safety and efficacy of autologous autologous skeletal muscle derived cells for patients with urge fecal incontinence due to external anal sphincter dysfunction caused by its disruption and/or weakness.
Timeline
- Start
- 2022-05-11
- Primary completion
- 2027-12-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aSMDC | Cell therapy | — | Other |
Indications
No indication recorded.